U.S. markets closed

NTLA Apr 2021 2.500 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
79.000.00 (0.00%)
As of 3:01PM EDT. Market open.
Full screen
Previous Close79.00
Open81.00
Bid65.50
Ask70.40
Strike2.50
Expire Date2021-04-16
Day's Range79.00 - 81.00
Contract RangeN/A
Volume2
Open Interest2
  • CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today
    InvestorPlace

    CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today

    A dramatically bearish analyst take has CRISPR stock Editas (NASDAQ:EDIT) down 15% in trading today, but it’s not the only one. Gene-editing stocks including Intellia Therapeutics (NASDAQ:NTLA) and CRISPR Therapeutics (NASDAQ:CRSP) are down 6% and 4% respectively. Source: vxhal/ShutterStock.com The downslide was triggered by Goldman Sachs initiating coverage of EDIT stock with a “sell” rating and a price target of just $20. Editas closed trading on Thursday at $40.98 and opened today at a price of $38.27. In his report, Goldman Sachs analyst Madhu Kumar expressed skepticism concerning the efficacy of EDIT’s experimental treatment for a rare eye disease. InvestorPlace analyst Luke Lango found Kumar’s report overly bearish, highlighting insider buying by the company’s CEO and a member of the board. Lango recommends investors buy EDIT stock on the dip.InvestorPlace - Stock Market News, Stock Advice & Trading Tips 10 Stocks at the Heart of Good Retirement Portfolios The decline in sector peers CRSP and NTLA appeared more sympathetic than tied to any particular news. CRISPR Therapeutics saw some gains earlier in the week which may help to explain why its stock deflated a little more than Intellia. Intellia has also seen increased investment from hedge funds in recent quarters, which could be a stabilizing force for NTLA stock. EDIT stock surged dramatically at the end of 2020 but has been steadily declining since a Jan. 8, 2021 peak above $90. The company has three other gene-editing treatments in progress, though none of those are as far along in development as its congenital amaurosis treatment. Editas reported full-year and Q4 earnings back in February. To learn more about investing in gene-editing stocks, check out our Guide to Investing in CRISPR Stocks. On the date of publication, Vivian Medithi did not have (either directly or indirectly) any positions in the securities mentioned in this article. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now The post CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today appeared first on InvestorPlace.

  • Is NTLA Stock A Buy or Sell?
    Insider Monkey

    Is NTLA Stock A Buy or Sell?

    In this article you are going to find out whether hedge funds think Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]

  • Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors
    GlobeNewswire

    Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors

    CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of Georgia Keresty, Ph.D., M.P.H., to the company’s Board of Directors. “Dr. Keresty's experience as a scientific and operational leader in our industry will be a great asset to Intellia as we continue to advance our research programs, expand our manufacturing capabilities and move towards delivering potentially curative therapies to patients globally,” said Intellia President and Chief Executive Officer John Leonard, M.D. Dr. Keresty brings more than 35 years of pharmaceutical industry experience to Intellia’s board, including leading the transition of novel therapeutic programs from preclinical to clinical development, and process development to commercial manufacturing. During her career, she has held key global roles in pharmaceutical research and development, operations, manufacturing and distribution, quality, compliance and regulatory affairs. Dr. Keresty recently served as chief operating officer and global head, medical sciences and development operations for Takeda Research and Development, a division of Takeda Pharmaceuticals USA, Inc. Prior to joining Takeda, Dr. Keresty served in leadership roles at Johnson & Johnson, including as vice president and global head, pharmaceutical development and manufacturing science; at Bristol-Myers Squibb Co., as vice president, worldwide quality and compliance; and at Novartis Pharmaceuticals Corporation as manufacturing site head. In addition to Intellia’s board, Dr. Keresty serves as a member of the board of directors of Aspen Technology, Inc., (NASDAQ: AZPN), an industrial asset optimization software company and Solid Biosciences, Inc., (NASDAQ: SLDB), a life science company. She is also a member of the board of directors of Commissioning Agents, Inc., a global engineering services firm, and the board of trustees for Clarkson University in Potsdam, New York. She previously served on the board of Janssen Alzheimer Immunotherapy and the board of trustees for the New Jersey Foundation for Aging, which is now called the NJ Advocates for Aging Well. Dr. Keresty earned B.Sc. degrees in Chemical Engineering from Clarkson University and Computer Science from Ramapo College, an M.S. in Information Systems from Pace University, an M.B.A. and Ph.D. in Operations Management from Rutgers Business School, and an M.P.H. in Global Health Leadership from the University of Southern California. About Intellia Therapeutics Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia’s combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products. Learn more about Intellia and CRISPR/Cas9 at intelliatx.com. Follow us on Twitter @intelliatweets. Forward-Looking Statements This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s ability to advance and expand the CRISPR/Cas9 technology to develop into human therapeutic products, as well as our CRISPR/Cas9 intellectual property portfolio; achieve stable or effective genome editing; the timing and potential achievement of milestones to advance our pipeline and grow as a company; and the anticipated contribution of the members of our board of directors and our executives to our operations and progress. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to Intellia’s relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for its product candidates; the risk that any one or more of Intellia’s product candidates will not be successfully developed, manufactured and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; the risk that Intellia may not be able to meet or comply with applicable laws and regulations, including clinical, manufacturing and commercialization requirements; and the risk that Intellia’s collaborations with Novartis Institutes for BioMedical Research, Inc. or Regeneron Pharmaceuticals, Inc. or its other ex vivo collaborations will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission (“SEC”). All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. Intellia Contacts: Investors:Lina LiDirectorInvestor Relations+1-857-706-1612lina.li@intelliatx.com Media:Julie FergusonInterim Head of External Affairs & Communications+1-312-385-0098julie.ferguson@intelliatx.com